Tag: InspireMD
CGuard Prime carotid stent gains US and European approvals for stroke...
InspireMD has been granted premarket approval (PMA) from the Food and Drug Administration (FDA) for its CGuard Prime carotid stent system in the U.S.—news...
InspireMD and NAMSA to partner on CGUARDIANS II pivotal clinical trial
InspireMD and North American Science Associates (NAMSA) today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct...
First patient enrolled in InspireMD’s CGUARDIANS II pivotal study
InspireMD today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime carotid stent system in...
InspireMD receives IDE approval from FDA for CGUARDIANS II pivotal trial
InspireMD has announced that the Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS II...
LINC 2024: C-GUARDIANS data represent lowest event rates in published trials...
New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent...